New drug trial hopes to tame Hard-to-Treat cancers
NCT ID NCT07369505
First seen Feb 01, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This early-stage study tests a new drug called Sapu003 in people with advanced cancers that are sensitive to mTOR treatment, including certain breast cancers, kidney cancer, and liver cancer. The main goal is to find the safest dose and understand side effects. About 27 adults will take part, receiving Sapu003 weekly by IV, sometimes with another drug called exemestane.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SOCRU
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.